Virology & Mycology Infectious Diseases
 
Untitled Document
   Publications A-Z
A
»Accounting & Marketing
» Addiction Research & Therapy
»Advances in Automobile Engineering
»Advances in Pharmacoepidemiology & Drug Safety
»Advances in Robotics & Automation
»Aeronautics & Aerospace Engineering
»Agrotechnology
»AIDS & Clinical Research
»Allergy & Therapy
»Air & Water borne Diseases
»Alzheimers Disease & Parkinsonism
»Analytical & Bioanalytical Techniques
»Anaplastology
»Anatomy & Physiology
»Andrology-Open Access
»Anesthesia & Clinical Research
»Antivirals & Antiretrovirals
»Applied & Computational Mathematics
»Applied Mechanical Engineering
»Aquaculture Research & Development
»Architectural Engineering Technology
»Arthritis
»Astrophysics & Aerospace technology
»Autacoids
»Autism-Open Access
  
B
»Bacteriology & Parasitology
»Bioanalysis & Biomedicine
»Biochemistry and Analytical Biochemistry
»Biochemistry & Pharmacology: Open Access
»Biochips & Tissue Chips
»Bioenergetics: Open Access
»Bioengineering & Biomedical Science
»Bioequivalence & Bioavailability
»Biofertilizers & Biopesticides
»Biometrics & Biostatistics
»Biomolecules
»Biochemistry & Physiology: Open Access
»Bioprocessing & Biotechniques
»Bioremediation & Biodegradation
»Biosafety
»Biosensors & Bioelectronics
»Biotechnology & Biomaterials
»Bioterrorism & Biodefense
»Blood Disorders & Transfusion
»Blood & Lymph
»Brain Disorders & Therapy
»Briefing in Intellectual Property Rights
»Business and Financial Affairs
  
C
»Cancer Science & Therapy
»Carcinogenesis & Mutagenesis
»Cell and Developmental Biology
»Cell Science & Therapy
»Chemical Engineering & Process Technology
»Chemotherapy: Open Access
»Chromatography & Separation Techniques
»Civil & Environmental Engineering
»Civil & Legal Sciences
»Clinical & Cellular Immunology
»Clinical Case Reports
»Clinical & Experimental Cardiology
»Clinical & Experimental Dermatology Research
»Clinical & Experimental Ophthalmology
»Clinical & Experimental Pathology
»Clinical & Experimental Pharmacology
»Clinical Pharmacology & Biopharmaceutics
»Clinical Research & Bioethics
»Clinical Toxicology
»Clinical Trials
»Cloning & Transgenesis
»Communicable & Noncommunicable Diseases
»Community Medicine & Health Education
»Computer Science & Systems Biology
»Cytology & Histology
D
»Data Mining in Genomics & Proteomics
»Defense Management
»Dentistry
»Depression and Anxiety
»Diabetes & Metabolism
»Drug Designing
»Drug Metabolism & Toxicology
  
E
»Earth Science & Climatic Change
»Ecosystem & Ecography
»Endocrinology & Metabolic Syndrome
»Entomology, Ornithology & Herpetology
»Environmental & Analytical Toxicology
»Epidemiology: Open Access
»Emergency Medicine: Open Access
»Ergonomics
»Electrical & Electronics
»Enzyme Engineering
»Entrepreneurship & Organization Management
  
F
»Fermentation Technology
»Fertilization : In Vitro
»Food Processing & Technology
»Forensic Research
»Forest Research: Open Access
»Fungal Genomics & Biology
  
G
»Gastrointestinal & Digestive System
»Genetic Syndromes & Gene Therapy
»Glycobiology
»Glycomics & Lipidomics
»Gynecology& Obstetrics
»Geography & Natural Disasters
»Geology & Geosciences
»Geophysics & Remote Sensing
»Gerontology & Geriatric Research
  
H
»Hair : Therapy & Transplantation
»Health & Medical Informatics
»Hereditary Genetics
»Homeopathy & Ayurvedic Medicine
»Hotel & Business Management
»Human Genetics & Embryology
»Hydrology: Current Research
»Hypertension- Open Access
  
I
»Industrial Engineering & Management
»Irrigation and Drainage Systems Engineering
»Information Technology & Software
Engineering
»Internal Medicine
  
L
»Liver
  
M
»Marine Science: Research & Development
»Mass Communication & Journalism
»Material Sciences & Engineering
»Medicinal Chemistry
»Medical Advancements in Genetic Engineering
»Medicinal & Aromatic Plants
»Medical Diagnostic Methods
»Medical Microbiology & Diagnosis
»Medical & Surgical Urology
»Membrane Science & Technology
»Metabolic Syndrome
»Metabolomics:Open Access
»Microbial & Biochemical Technology
»Molecular Biology
»Molecular Biomarkers & Diagnosis
»Molecular Imaging & Dynamics
»Mycobacterial Diseases
N
»Nanomedicine & Biotherapeutic Discovery
»Nanomedicine & Nanotechnology
»Neonatal Biology
»Nephrology & Therapeutics
»Neurology & Neurophysiology
»Novel Physiotherapies
»Nuclear Energy & Power Generation
Technologies
»Nuclear Medicine & Radiation Therapy
»Nutrition & Food Sciences
»Nutritional Disorders & Therapy
»Nursing & Care
  
O
»Obesity & Weight loss Therapy
»Outlook on Developing Drugs: Open Access
»Organ Biology
»Organic Chemistry: Current Research
»Orthopedic & Muscular System: Current Research
»Otolaryngology
  
P
»Pain & Relief
»Palliative Care & Medicine
»Pancreatic Disorders & Therapy
»Pediatrics & Therapeutics
»Petroleum & Environmental Biotechnology
»Pharmaceutica Analytica Acta
»Pharmaceutical Regulatory Affairs: Open Access
»Pharmaceutics & Drug Delivery Research
»Pharmacogenomics & Pharmacoproteomics
»Physical Chemistry & Biophysics
»Plant Pathology & Microbiology
»Powder Metallurgy & Mining
»Primatology
»Primary Health Care: Open Access
»Proteomics & Bioinformatics
»Psychology & Psychotherapy
»Pulmonary & Respiratory Medicine
  
R
»Radiology: Open Access
»rDNA Technology
»Reproductive System & Sexual Disorders
»Rheumatology: Current Research
  
S
» Single Cell Genomics & Proteomics
»Sleep Disorders & Therapy
»Social & Economical Issues of Biotechnology
»Socialomics
»Sports Medicine & Doping Studies
»Spine
»Stem Cell Research & Therapy
»Steroids & Hormonal Science
»Stock & Forex Trading
»Surgery: Current Research
  
T
»Telecommunications System & Management
»Textile Science & Engineering
»Thermodynamics & Catalysis
»Thyroid Disorders & Therapy
»Tissue Science & Engineering
»Translational Medicine
»Transplantation Technologies & Research
»Trauma & Treatment
»Tourism & Hospitality
  
V
»Vaccines & Vaccination
»Veterinary Science & Technology
»Virology & Mycology
»Vitamins & Trace Elements
  
W
»Women's Health Care
  
Y
»Yoga & Physical Therapy
 
   Browse by Subjects
Clinical
»Clinical & Experimental Pharmacology
»Forensic Research
»Cell Science & Therapy
»Stem Cell Research & Therapy
»Cancer Science & Therapy
»Carcinogenesis & Mutagenesis
»Cytology & Histology
»AIDS & Clinical Research
»Anesthesia & Clinical Research
»Transplantation Technologies & Research
»Clinical Research & Bioethics
»Clinical & Cellular Immunology
»Clinical & Experimental Cardiology
»Clinical & Experimental Dermatology Research
»Clinical & Experimental Ophthalmology
»Neurology & Neurophysiology
»Clinical & Experimental Pathology
»Pulmonary & Respiratory Medicine
»Clinical Toxicology
  
Pharmaceutical Sciences
»Vaccines & Vaccination
»Antivirals & Antiretrovirals
»Bioanalysis & Biomedicine
»Drug Metabolism & Toxicology
»Bioequivalence & Bioavailability
»Pharmaceutica Analytica Acta
»Pharmaceutics & Drug Delivery Research
»Clinical Pharmacology & Biopharmaceutics
»Outlook on Developing Drugs: Open Access
»Pharmacoepidemiology & Drug Safety
»Pharmaceutical Regulatory Affairs: Open Access
  
Chemistry
»Thermodynamics & Catalysis
»Physical Chemistry & Biophysics
»Organic Chemistry
»Chromatography & Separation Techniques
»Analytical & Bioanalytical Techniques
»Medicinal Chemistry
  
Environmental
»Earth Science & Climatic Change
»Environmental & Analytical Toxicology
»Aquaculture Research & Development
»Hydrology: Current Research
»Petroleum & Environmental Biotechnology
»Ecosystem & Ecography
  
Omics
»Pharmacogenomics & Pharmacoproteomics
»Data Mining in Genomics & Proteomics
»Proteomics & Bioinformatics
»Computer Science & Systems Biology
»Health & Medical Informatics
»Glycomics & Lipidomics
»Metabolomics:Open Access
  
Life Sciences
»Agrotechnology
»Marine Science: Research & Development
»Veterinary Science & Technology
»Plant Pathology & Microbiology
»Nutrition & Food Sciences
»Bioremediation & Biodegradation
»Biometrics & Biostatistics
»Bioengineering & Biomedical Science
»Microbial & Biochemical Technology
»Bioterrorism & Biodefense
»Biofertilizers & Biopesticides
»Social & Economical Issues of Biotechnology
»Biosensors & Bioelectronics
»Nanomedicine & Biotherapeutic Discovery
»Biochips & Tissue Chips
»Molecular Imaging & Dynamics
»Yoga & Physical Therapyy
»Tissue Science & Engineering
»Biotechnology & Biomaterials
»Biochemistry and Analytical Biochemistry
»Nanomedicine & Nanotechnology
»Membrane Science & Technology
»Bacteriology & Parasitology
»Enzyme Engineering
»rDNA Technology
»Cell and Developmental Biology
»Fermentation Technology
»Chemotherapy
»Biochemistry & Physiology
»Biomolecules
»Biochemistry & Physiology: Open Access
»Biochemical Pharmacology
»Bioenergetics
»Forest Research
»Fungal Genomics & Biology
»Medical Advancements in Genetic Engineering
»Biosafety
»Medicinal & Aromatic Plants
» Single Cell Genomics & Proteomics
»Vitamins & Trace Elements
»Women's Health Care
»Primatology
  
Engineering
»Advances in Automobile Engineering
»Advances in Robotics & Automation
»Aeronautics & Aerospace Engineering
»Applied Mechanical Engineering
»Architectural Engineering Technology
»Bioprocessing & Biotechniques
»Chemical Engineering & Process Technology
»Civil & Environmental Engineering
»Electrical & Electronics
»Food Processing & Technology
»Geology and Geosciences
»Geophysics & Remote sensing
»Industrial Engineering & Management
»Information Technology & Software
Engineering
»Irrigation and Drainage Systems Engineering
»Material Sciences& Engineering
»Powder Metallurgy & Mining
»Telecommunications System & Management
»Textile Science & Engineering
  
Medical Sciences
»Genetic Syndromes & Gene Therapy
»Steroids & Hormonal Science
»Virology & Mycology
»Communicable & Noncommunicable Diseases
»Molecular Biomarkers & Diagnosis
»Psychology & Psychotherapy
»Nuclear Medicine & Radiation Therapy
»Alzheimers Disease & Parkinsonism
»Dentistry
»Pediatrics & Therapeutics
»Rheumatology: Current Research
»Hereditary Genetics
»Reproductive System & Sexual Disorders
»Addiction Research & Therapy
»Allergy & Therapy
»Diabetes & Metabolism
»Blood Disorders & Transfusion
»Endocrinology & Metabolic Syndrome
»Nutritional Disorders & Therapy
»Medical Microbiology & Diagnosis
»Human Genetics & Embryology
»Gastrointestinal & Digestive System
»Otolaryngology
»Anatomy & Physiology
»Autacoids
»Sports Medicine & Doping Studies
»Nephrology & Therapeutics
»Community Medicine & Health Education
»Translational Medicine
»Entomology, Ornithology & Herpetology
»Orthopedic & Muscular System
»Epidemiology: Open Access
»Gynecology& Obstetrics
»Mycobacterial Diseases
»Anaplastology
»Surgery: Current Research
»Radiology: Current Research
»Internal Medicine
»Blood & Lymph
»Emergency Medicine
»Fertilization : In Vitro
»Palliative Care & Medicine
»Glycobiology
»Ergonomics
»Liver
»Neonatal Biology
»Medical Diagnostic Methods
»Hair: Therapy & Transplantation
»gerontology & Geriatrics Research
»Andrology
»Clinical Case Reports
»Spine
»Pain & Relief
»Depression and Anxiety
»Obesity & Weight loss Therapy
»Sleep Disorders & Therapy
»Nursing & Care
»Trauma & Treatment
»Primary Health Care: Open Access
»Clinical Trials
»Homeopathy & Ayurvedic Medicine
»Brain Disorders & Therapy
»Pancreatic Disorders & Therapy
»Metabolic Syndrome
»Novel Physiotherapies
»Thyroid Disorders & Therapy
»Air & Water borne Diseases
»Drug Designing
»Molecular Biology
»Cloning & Transgenesis
»Hypertension-Open Access
»Organ Biology
»Arthritis
 
Management
»Accounting & Marketing
»Business and Financial Affairs
»Civil & Legal Sciences
»Defense Management
»Entrepreneurship& Organization Management
»Hotel & Business Management
»Industrial Engineering & Management
»Mass Communication & Journalism
»Stock & Forex Trading
» Socialomics
»Tourism & Hospitality
 
   Conferences
Upcoming Conferences
»International Conference and Exhibition on Metabolomics & Systems Biology 20-22 February 2012 San Francisco, USA.
»2nd World Congress on Pharmaceutics & Novel Drug Delivery Systems 20-22 February 2012 San Francisco, USA.
»International Conference and Exhibition on Biometrics & Biostatistics 5-7 March 2012 Omaha, USA.
»2nd World Congress on Clinical & Experimental Dermatology 5-7 March 2012 Omaha, USA
»2nd World Congress on Clinical & Experimental Cardiology 5-7 March 2012 Omaha, USA.
» 2nd World Congress on Clinical & Experimental Ophthalmology 5-7 March 2012 Omaha, USA.
»International Conference & Exhibition on Nanotechnology and Nanomedicine 12-14 March 2012 Omaha, USA.
»World Congress on Gastroenterology and Urology 12-14 March 2012 Omaha, USA
»3rd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit 26-28 March 2012 Marriott Hotel, Hyderabad, India.
» International Conference and Exhibition on Neurology &Therapeutics 14-16 May 2012 Renaissance Las Vegas Hotel, Las Vegas, Nevada, USA.
»International Conference and Exhibition on Biosensors & Bioelectronics14-16 May 2012 Las Vegas, USA.
»3rd world Congress on Biomarkers & Clinical Research 2-4 July 2012 Las Vegas, USA.
»2nd world Congress on Proteomics & Bioinformatics 2-4 July 2012 Las Vegas, USA.
»International Conference and Exhibition on Orthopedics 13-15 August 2012 Chicago, USA.
»International Conference and Exhibition on Rheumatology and Therapeutics 14-15 August 2012 Chicago, USA.
»International Conference and Exhibition on Addiction Research & Therapy 20-22 August 2012 Las Vegas, USA.
»2nd World Congress on Virology 20-22 August 2012 Las Vegas, USA.
»International Conference and Exhibition on Nephrology and Therapeutics 20-22 August 2012 Hilton Chicago/Northbrook Chicago, USA.
»2nd World Congress on Vaccines & Vaccination 20-22 August 2012 at Chicago, USA.
»World Congress on Earth Science & Climate Change 21-22 August 2012 Chicago, USA.
»International Conference and Exhibition on pathology 27-29 August 2012 Philadelphia, USA.
»International Conference on Pulmonary & Respiratory Medicine 27-29 August 2012 Philadelphia, USA.
»International Conference and Exhibition on Nutritional Science & Therapy-2012 27-29 August 2012 Philadelphia, USA.
»International Conference on Central Nervous System 5-7 September 2012 Double by Hilton Philadephia, USA.
»International Conference on Occupational Health and Safety Summit 5-7 September 2012 Philadelphia, USA.
»International Conference on Hydrology and Groundwater Expo 10-12 September 2012 Hilton San Antonio Airport, USA.
»2nd World Congress on Cancer Science & Therapy 10-12 September 2012 San Antonio, USA.
»World Congress and Expo on Biowaivers and Biosimilars 10-12 September 2012 San Antonio, TX, USA.
»3rd World Congress on Biotechnology 13-15 September 2012 HICC, Hyderabad, India.
»International Conference on Biodiversity & Sustainable Energy Development 14-15 September 2012 Hyderabad, India.
»World Toxicology Summit & Expo-2012 17-19 September 2012 San Antonio Texas, USA.
»International Conference and Exhibition on Translational medicine-2012, 24-26 September 2012 Chicago USA.
»3rd World Congress on Diabetes & Metabolism which is to be held on 24-26 September 2012 Marriott Convention Center, Hyderabad, India.
»International Conference on Tissue Science and Engineering 1-3 October 2012 San Francisco, USA.
»International conference and Exhibition on Pharmacovigilance and Clinical Trials 1-3 October 2012 San Francisco, USA.
»Omics International Integrative Biology Summit 2012 1-3 October 2012 San Francisco, USA.
»International Conference & Exhibition on Emerging Cell Therapies 1-3 October 2012 San Francisco, USA.
»World Congress on Forensic Research & Technology 15-17 October, 2012 at DoubleTree by Hilton Chicago-North Shore, USA.
»International Conference and Exhibition on Otolaryngology 15-17 October 2012 Chicago, USA.
»International conference on Biothreats and Biodefense 15-17 October, 2012 at DoubleTree by Hilton Chicago-North Shore, USA.
»International Conference on Genetic Syndromes & GeneTherapy 22-24 October 2012 at DoubleTree by Hilton Chicago-North Shore, USA.
»International Conference on Clinical and Cellular Immunology 22-24 October 2012 Las Vegas, USA.
»International Conference and Expo on Material science and Engineering 22-24 October 2012 DoubleTree by Hilton Chicago-North Shore, USA.
» International Expo and Conference on Analytrix & HPLC 22-24 October 2012 Hilton Northbrook, Chicago, USA.
»International Conference and Exhibition on Computer Aided Drug Design & QSAR 29-31 October 2012, Chicago, USA.
»World Congress on Personalised Medicine & Molecular Diagnostics 12-14 November 2012 San Antonio, USA.
»2nd World Congress on Cell Science and Stem Cell Research 12-14 November 2012 Hilton San Antonio Airport, USA.
»International Conference on Clinical Microbiology & Microbial Genomics 12-14 November 2012 San Antonio, USA.
»World Congress on Regenerative and Functional Medicine 12-14 November 2012 at San Antonio, Texas, USA.
»Global Biofuels and Bioproducts Summit 19-21 November 2012 San Antonio, USA.
»International Conference and Exhibition on Probiotics-2012, 19-21 November 2012, Hilton San Antonio Airport, USA.
»International Conference and Exhibition on Food Processing and Technology 22-24 November 2012 Hyderabad, India.
»2nd World Congress on Pharmaceutical Regulatory Affairs 23-24 November 2012 HICC Hyderabad, India
»International Conference and Exhibition on Cosmetology & Cosmetics 23-24 November 2012 HICC Hyderabad, India.
»International Conference and Exhibition on Surgery & Transplantation 26-28 November 2012 Hilton San Antonio Airport, USA.
»International conference on Hair Transplantation and Trichology 26-28 November 2012 San Antonio, USA.
»World Congress on Novel approaches in Anaesthesia and Preoperative Care during 26-28 November 2012 San Antonio, USA.
»International Conference on Obesity and Weight Management 3-5 December 2012 Philadelphia, USA.
Previous Conferences Organized/Co-organized
»2nd world Congress on Analytical and Bioanalytical Techniques 16-17 December 2011San franscico, USA.
»2nd World Congress on Diabetes & Metabolism 6-8 December 2011 Philadelphia, USA.
»World Congress on Pediatrics & Gynecology 6-8 December 2011 Philadelphia, USA.
»International Conference and Exhibition on Cell Science & Stem Cell Research 29 Nov-1 Dec 2011 Philadelphia, USA.
»2nd World Congress on Biotechnology 29 Nov -1 Dec 2011 Philadelphia, USA.
»International Conference and Exhibition on Vaccines & Vaccination 22-24 November 2011 Philadelphia, USA.
»2nd World Congress on Biomarkers & Clinical Research 12-14 September 2011 Baltimore, USA.
»International Conference and Exhibition on Virology 5-7 September 2011 Baltimore, USA.
»International Conference and Exhibition on Pharmaceutical Regulatory Affairs 6-7 September 2011 Baltimore, USA.
»International Conference and Exhibition on Cancer Science & Therapy 15-17 August 2011 Las Vegas, USA.
»International Conference on Clinical Research: Dermatology, Ophthalmology and Cardiology 5-6 July 2011 San Francisco, USA.
»International Conference & Exhibition on Proteomics & Bioinformatics 6-8 June 2011 HICC, Hyderabad, India.
»International Conference & Exhibition on Pharmaceutical Biotechnology 6-8 June 2011 HICC, Hyderabad, India.
»2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit 6-8 June 2011 Las Vegas, USA.
»International Conference on Pharmaceutics & Novel Drug Delivery Systems 7-8 June Las Vegas, USA.
»World Congress on Biotechnology 21-23 March 2011 Hyderabad, India.
»International Conference on Diabetes and Metabolism 13-14 December 2010 Santa Clara, USA.
»International Conference on Biomarkers & Clinical Research 22-23 November 2010 Santa Clara, USA
»International Conference and Exhibition on Analytical and Bioanalytical Techniques: Pharmaceutical R & D Summit 01 - 03 November 2010 Hyderabad, India
»International Conference & Exhibition on Bioequivalence & Bioavailability 2010, Pharmaceutical R & D Summit March 01-03, 2010.
»Integrating Glycomics with other Omics in Cancer Detection and Diagnosis, January 19-20, 2010, Stanford University School of Medicine.
»3rd World Congress of Gene-2009, December 1-7, 2009.
»7th Annual World Congress of International Drug Discovery Science & Technology, October 22-25.
»2nd WSA-2009, July 18-20, 2009
»1st CCSB-2009, February 16-17, 2009
»2nd PRICPS-4th AOHUPO, June 22-26, 2008
»95th ISCA, January 5-8, 2008

Search :     Advanced Search 

Home   |   Join   |   Contact     

    
Journal Details
 
 
Research Article Open Access
The Influence of Formula Concentration on the Absorption of Darbepoetin Alfa after Subcutaneous Administration
Tomonori Tayama1*, Kazuki Kawakami1, Hirotaka Takama1, Daisuke Nakashima1, Hideji Tanaka1, Takayuki Tsuji2, Tatsuo Yamamoto3, Sakuo Hoshi4 and Tadao Akizawa5
1Development Division, Kyowa Hakko Kirin Company Ltd., 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan
21st Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu-shi, Shizuoka, 431-3192, Japan
3Faculty of Health Promotional Sciences, Department of Health and Nutritional Science, Hamamatsu University. 1230 Miyakoda-cho, Kita-ku, Hamamatsu-shi, shizuoka, 431-2102, Japan
4Pharmaco-Business Innovation, Graduate School of Pharmaceutical Sciences, Faculty of Pharmaceutical Science, The University of Tokyo. 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8654, Japan
5Department of Nephrology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
*Corresponding author: Dr. Tomonori Tayama
Development Division
Kyowa Hakko Kirin Company Ltd., 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo,
100-8185, Japan,
Tel: +81-3-3282-0983,
Fax: +81-3-3282-0335,
E-mail: tomonori.tayama@kyowa-kirin.co.jp
 
Received November 10, 2009; Accepted December 21, 2009; Published December 22, 2009
 
Citation: Tayama T, Kawakami K, Takama H, Nakashima D, Tanaka H, et al. (2010) The Influence of Formula Concentration on the Absorption of Darbepoetin Alfa after Subcutaneous Administration. J Bioequiv Availab 2: 001-005. doi:10.4172/jbb.1000021
 
Copyright: © 2010 Tayama T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 
Abstract
 
Darbepoetin alfa (DA) is a hyperglycosylated analog of recombinant human erythropoietin (rHuEPO) that stimulates red blood cell production. The aim of this study is to investigate the influence of formula concentration on the absorption of DA after subcutaneous administration. Three separate studies were performed to assess the bioequivalence of four different formula concentrations of DA, 100 μg/ml as reference concentration, comparing with 10, 30, 200 μg/ml as test concentration, by the same dosage (60 μg). The mean values of the pharmacokinetic parameters were similar after subcutaneous administration in each study. The 90% confidence intervals for logtransformed Cmax and AUC0-t were within the bioequivalence criteria (0.8-1.25) in each study. In previous studies, the effect in absorption process of insulin was correlated to the formula concentration, the formula concentration of human growth hormone might not affected its absorption. The molecular weight is thought to be causally related to these results. The absorption rate of DA is not affected by its formula concentration because DA, which has relatively higher molecular weight (36,000 Da), is primarily absorbed slowly via lymph vessels regardless of its concentration.
 
Keywords
 
Darbepoetin alfa; Absorption; Formula concentration; Subcutaneous administration; Bioequivalence
 
Introduction
 
Darbepoetin alfa (DA) is the hyperglycosylated analog of recombinant human erythropoietin (rHuEPO) that stimulates red blood cell production (erythropoiesis) by the same mechanism as rHuEPO (Macdougall, 2000). DA is a 165-amino acid protein containing five N-linked oligosaccharide chains, whereas rHuEPO has only three N-linked oligosaccharide chains (Egrie et al., 2001). The additional oligosaccharide chains increase the molecular mass of the glycoprotein from approximately 30,400 to 36,000 Da and the mean terminal half life of DA in non-dialysis patients after a single subcutaneous administration was found to be longer than that reported for subcutaneous administration of rHuEPO (Padhi et al., 2006).
 
There are a number of factors that modify the subcutaneous absorption profiles. A typical factor is the concentration of drug at the absorption site. The rate of transfer by most transport processes depends on the concentration difference between the two sides of the membrane (Gram, 1990).
 
There have been a few studies that investigated the influence of formula concentration on the absorption of insulin and human growth hormone (hGH) which are typical macromolecular drugs (Chantelau et al., 1985; Hildebrandt et al., 1983; Laursen et al., 1994; Blok et al., 1991; Vahl et al., 1996). Although DA is one of the macromolecular drugs, it has not yet been investigated from the same point of view. When subcutaneous administered, the formula concentration affects the absorption of insulin while that of hGH has not affect after subcutaneous administration. We think that these results are derived from the molecular weight differences (Insulin : 5,800 Da, hGH : 22,000 Da). Therefore, we verified the effects of the formula concentrations of DA, which has higher molecular weights (36,000 Da), on its absorption rate after subcutaneous administration, using three bioequivalence studies.
 
Materials and Methods
 
Subject
 
Healthy male adults, 20-45 years of age and body mass indices of 18-26 kg m-2, were enrolled for three separate studies. Each study was approved by the investigators’ institutional review board and all the subjects gave their informed consents in writing prior to the studies. Each subject was deemed to be healthy on the basis of normal medical history, physical examination, electrocardiogram and laboratory tests (routine hematologic test, serum biochemistry, urinalysis, hepatitis B surface antigen, hepatitis C antigen, and human immunodeficiency virus antibody). The subjects were asymptomatic without known disease. Subjects were instructed to restrict smoking, taking other medications or alcohol and to avoid strenuous exertion throughout the study. These studies were conducted in compliance with the Good Clinical Practice regulations/guidelines and in accordance with the Declaration of Helsinki and subsequent amendments on experimentation in humans were obtained in all respects.
 
Study design
 
Three separate studies were performed to assess the bioequivalence of four different formula concentrations of DA: the reference formulation was 100 μg/ml and test formulations were 10 μg/mL (Study 1), 30 μg/mL (Study 2) and 200 μg/mL (Study 3), respectively. Each study was a single-centre, openlabel, randomized, two-treatment, two-period, crossover study. Using a 1:1 allocation ratio, subjects were randomized to one of the two treatment-sequence groups to receive either reference formulation or test formulation of DA to a dose of 60 μg as their first subcutaneous administration (Period 1). In Period 2, the subjects subcutaneously received the alternate treatment after washout period. The choice of the dose for the studies was based upon the following criteria. To obtain adequate pharmacokinetic profiles and to minimize the influence of changes in the production of endogenous erythropoietin, a higher dose is preferable for a bioequivalence study. On the other hand, a higher dose of erythropoietin results in an increase in haematocrit and raises safety concerns and the carry-over effect on pharmacokinetics. Therefore we chose 60 μg per subject as the most appropriate dose. It was planned that a total of up to 30 (Study 3) or 32 (Study 1 and 2) subjects, 15 (Study 3) or 16 (Study 1 and 2) subjects in each period, received DA in each study. Sample size was settled based on the results of the previous bioequivalence study using the different formulations of the same concentration. Subjects who withdrew from the study before completion were not to be replaced.
 
Each eligible subject was subcutaneously administered single dose of the reference and the test formulation over 41-day washout period which was inserted between each study period. The injections of 10 μg/mL formulation were carried out subcutaneously in six sites of both upper arms. Those of 30 μg/mL, 100μg/mL and 200 μg/mL formulations were administered subcutaneously in two sites, one site each of upper arm, respectively. This over 41-day time frame was to allow for the red blood cell counts to return to baseline and the elimination of DA. Blood samples (2 mL) for the determination of serum concentration of DA were obtained before and after administration at exactly the following time points; 1, 2, 5, 8, 12, 24, 36, 48, 72, 96, 120, 168, 240 and 336 hr. Serum samples obtained by centrifugation were stored frozen until analysis.
 
Serum darbepoetin alfa measurements
 
Serum samples were analyzed with the use of the Quantikine in vitro diagnostics rHuEPO enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA). The standard curve was constructed using DA, and quality control samples ensured individual assay quality. In validation tests, the intra- and inter-assay precision for spiked samples ranged from 5.1% to 11.0% and 4.4% to 6.1%, respectively, and the intraand inter-assay accuracy ranged from -11.0% to -4.8% and from -10.7% to 8.4%, respectively. The inter-assay precision and accuracy criterion for clinical serum samples were within 15% and± 15%, respectively. The range of detectable concentration for DA in serum was from 0.078 ng/mL to 5.00 ng/mL. The ELISA for the pharmacokinetic investigation was performed at SRL Inc. (Tokyo and Kanagawa, Japan).
 
Pharmacokinetic analysis
 
For pharmacokinetic analyses, the predose serum concentration of endogenous erythropoietin for each treatment period was subtracted from all the postdose DA concentrations for each subject to adjust for the baseline erythropoietin level (DA and endogenous erythropoietin show a cross-reaction in the ELISA). The predose mean serum concentrations of endogenous level for each treatment period were 0.169 - 0.195 ng/mL and subtracted from all the postdose DA concentrations for each subject.
 
WinNonlin version 5.2 (Pharsight Corp., Mountain View, CA, USA) was used throughout the pharmacokinetic analyses. For the maximum serum drug concentration (Cmax) and the time to maximum serum drug concentration (Tmax), we used the observed values. The area under the serum concentration-time curve from zero to the time of the last quantifiable concentration (AUC0-t) was calculated according to the linear/log trapezoidal method using the actual times of measurements.
 
Statistical analysis
 
Statistical analysis was performed using the SAS System for Windows, Version 8.2 (SAS Institute, Inc., Cary, NC, USA). The point estimates and the 90% confidence intervals (CI) for the ratios of the geometric mean values of Cmax and AUC0-t and the difference of the arithmetic mean values of Tmax for the test and reference formulation were calculated.
 
Results
 
Healthy male adults (20 - 39 years) were enrolled for each study.
 
The serum concentration-time profiles of test formulation were similar to those of reference formulation in all studies (Figure 1). After the administration, the mean serum concentration increased slowly, and reached the maximum concentration at 36 hr postdose.
 
fig
 Figure 1: Mean observed serum DA concentration after subcutaneous administration in healthy male adults. Healthy male adults subjects received administrations of (Study 1) 10 μg/mL or 100 μg/mL, (Study 2) 30 μg/mL or 100 μg/ mL, (Study 3) 200 μg/mL or 100 μg/mL (60 μg per subject). Standard deviations are indicated by error bars.
 
The pharmacokinetic parameters of each formulation are summarized in Table 1. The mean value of Cmax, AUC0-t and Tmax were similar in all studies.
 
Table 1: Pharmacokinetic parameters of DA after subcutaneous administration.
SD =standard deviation, Cmax= the maximum serum drug concentration, AUC0-t= the area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration, Tmax= the time to maximum serum drug concentration.
*1: One subject was excluded, because the AUC could not be estimated accurately due to the lack of 336 hr data.
*2: One subject was excluded, because the AUC was overestimated due to the deviations of the last sampling point.
 
The point estimates and 90% CI of the ratios for log-transformed AUC0-t, log-transformed Cmax, and Tmax are shown in Table 2. All the ratios for log-transformed AUC0-t and Cmax were within the bioequivalence criteria (0.80-1.25).
 
Table 2: Bioequivalence analysis for pharmacokinetic parameter among 4 formulations.
Cmax= the maximum drug concentration, AUC0-t= the area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration, Tmax= the time to maximum serum drug concentration.
 
The safety profile was described by summarizing the nature, frequency, severity, and relationship to treatment of all adverse events; changes from baseline in laboratory hematology and biochemistry variables and in vital signs (blood pressure, heart rate and temperature), use of concomitant medications, and formation of antibodies to darbepoetin alfa and epoetin alfa. The overall incidence of adverse events was evenly distributed across all treatment groups, and no serious adverse events were reported. The overall safety data were consistent with those expected in a healthy study population, and did not present any concerns that suggests adverse effects due to formulation concentrations. Mean values for laboratory hematology and biochemistry variables (including hemoglobin) and vital signs were stable throughout the study. No antibodies were observed in any subject during the study.
 
Discussion
 
In three separate studies, the mean values of Cmax, AUC0-t and Tmax of reference and test formulation were similar after subcutaneous administration. The 90% CI of the ratios of the log-transformed for AUC0-t and Cmax were within 0.80-1.25. These results suggest that the formula concentration of DA does not affect its absorption after subcutaneous administration. Incidentally, it was difficult to investigate the potential impact of demographic characteristics in this study since demographic characteristics of healthy young volunteers in these studies were very similar. It was reported that the absorption rate constant of DA declined with age in a study using 20 - 80 years old subjects (Agoram et al., 2006). Also, it would appear that there was little influence of injection sites and injection times on absorption kinetics of subcutaneously administered DA in this study. Tolerable volume for subcutaneous administration is limited, therefore, we used multiple dosing in some dosing groups. In addition, it was reported that there was little influence of injection sites on the absorption of rHuEPO (30,400 Da), which is similar as DA in molecular weight (Jensen et al., 1994).
 
Some studies investigated the influence of formula concentration on the absorption of insulin and hGH which are typical macromolecular drugs (Chantelau et al., 1985; Hildebrandt et al., 1983; Laursen et al., 1994; Blok et al., 1991; Vahl et al., 1996).
 
In this previous study (Chantelau et al., 1985), the comparison of insulin pharmacokinetics was performed after its subcutaneous administration of several formula concentrations, 15, 40 and 100 units/ml, given in the same amount (10 units). This study suggested that insulin of low concentration was absorbed faster from the subcutaneous tissues than insulin of high concentration. Also, another study showed that the absorption of U40 insulin (40 units/mL) was significantly faster than of that of U100 insulin (100 units/mL), when given in the same amount (8 units) (Hildebrandt et al., 1983).
 
In the study of hGH (Laursen et al., 1994), the comparison of its pharmacokinetics was performed after subcutaneous administration of two formula concentrations, 12 and 56 IU/mL. The patients received in random order a subcutaneous injection of 3 IU/m2 of hGH. This study suggested that the absorption kinetics of the formulations of hGH containing 12 IU/mL and 56 IU/mL were similar. Another study also showed that hGH bioavailability with pen injection (4 IU/mL) was equals to that of injection by syringe (12 IU/mL) (Blok et al., 1991). The patients received in random order a subcutaneous injection of 3 IU/m2 of hGH. When given in the same amount (3 IU/m2), the changes observed in the pharmacokinetics of hGH among three different preparations, Norditropin 4IU/mL, 5.9 IU/mL and 11.7 IU/mL, were moderate (Vahl et al., 1996).
 
The molecular weight is thought to be causally related to these results. In a diffusion-controlled process, large molecular is expected to have a slower penetration rates than smaller ones. A primary factor in the relatively-fast absorption rate of insulin is presumed to be its molecular weight of 5,800 Da, which is close to the upper limit for transcapillary absorption (Kraegen et al., 1985; Schou, 1961). hGH with a molecular weight of 22,000 Da is absorbed more slowly than insulin after subcutaneous administration (Russo and Moore, 1982). In rat muscle, there was a 10-fold difference in clearance rates of labeled carbohydrates, with molecular weight ranging from 182 to 90,000. However, for small molecules, the absorption rate is similar and is limited by blood flow (Sund and Schou, 1964; Bederka et al., 1971). It appears that molecules of low molecular weight are primarily absorbed via the capillaries, while molecules having relatively higher molecular weight are absorbed primarily via lymph vessels (Barnes and Trueta, 1941). In sheep model, the lymphatic absorption of group compounds with increasing molecular weights (5-fluoro-2’-deoxyridine, 2,500 Da; inulin, 5,200 Da; cytochrome C, 12,300 Da; IFN-α, 19,000 Da) showed a direct correlation between molecular weight and the extent of popliteal lymph recovery (Supersaxo et al., 1990; Supersaxo et al., 1991). Furthermore in sheep model, 48% of the systemic bioavailability of insulin following subcutaneous administration was contributed by the lymphatic system (Charman et al., 2001). Likewise, erythropoietin with a molecular weight of 30,400 Da demon- strated lymphatic uptake of 83.9% of the injected dose (McLennan et al., 2005). This different absorption pathway may be related to structural differences between blood and lymphatic endothelial cell lining. The endothelia lining of the blood capillaries have a continuous and uninterrupted subendothelial basement. In contrast, terminal lymphatics does not possess this membrane. The lack of a basal lamia around lymphatic capillaries may be the major functional importance in facilitating access of interstitial macromolecules to the lymphatic system (O’Morchoe and O’Morchoe, 1987). In addition, adjacent endothelial cells of terminal lymphatics may have gaps which makes it possible for macromolecules that goes up to 1 μm diameter to enter the lymphatics (Leak, 1971).
 
As described above, we presented following hypothesis; absorption profiles of small molecular are affected by the drug concentration because both drug and medium goes through blood capillaries at the same time. Macromolecule is primarily absorbed via lymph vessels slowly and does not go through the blood capillaries as medium does. In other words, absorption rate of macromolecule is not affected by the formula concentration since it is primarily absorbed slowly via lymph vessels regardless of its concentration. The data shown in this study was limited to DA and there has been few studies investigated as similar point of view in other macromolecular drugs. However, the data which can confirm the presented hypothesis, will be available in the near future because many macromolecular drugs will are under development. The conclusion of this study is that the formula concentration of DA, which is one of the macromolecular drugs, does not affect its absorption rate after subcutaneous administration as hypothesis above.
 
Acknowledgements
 
We thank Shiho Noda and our colleagues in Kyowa Hakko Kirin Company Ltd for their excellent technical assistance.
 
References
 
  1. Agoram B, Sutjandra L, Sullivan JT (2006) Population pharmacokinetics of darbepoetin alfa in healthy subjects. Br J Clin Pharmacol 63: 41-52. »  CrossRef  »  PubMed  »  Google Scholar

  2. Barnes JM, Trueta J (1941) Absorption of bacteria, Toxins and snake Venoms from the Tissues. The Lancet Office 1: 623-6.  »  Google Scholar

  3. Bederka J, Takemori AE, Miller JW (1971) Absorption rates of various substances administered intramuscularly. Eur J Pharmacol 15: 132-6. »  CrossRef  »  PubMed  »  Google Scholar

  4. Blok GJ, van der Veen EA, Susgaard S, Lausen F (1991) Influence of concentration and injection volume on the bioavailability of subcutaneous growth hormone: comparison of administration by ordinary syringe and by injection pen. Pharmacol Toxicol 68: 355-9.  »  CrossRef »  PubMed  »  Google Scholar

  5. Chantelau E, Sonnenberg GE, Rajab A, Römisch J, Berger M (1985) Absorption of subcutaneously administered regular human and porcine insulin in different concentrations. Diabete Metab 11: 106-10.  »  PubMed  »  Google Scholar

  6. Charman SA, McLennan DN, Edwards GA, Porter CJ (2001) Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model. Pharm Res 18: 1620-6. »  CrossRef  »  PubMed  »  Google Scholar

  7. Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16: 3- 13. »  CrossRef  »  PubMed  »  Google Scholar

  8. Gram TE (1990) Drug absorption and distribution. Modern pharmacology 3rd edn 21-38.

  9. Hildebrandt P, Sestoft L, Nielsen SL (1983) The absorption of subcutaneously injected short-acting soluble insulin : Influence of injection technique and concentration. Diabetes Care 6: 459-62. »  CrossRef »  PubMed  »  Google Scholar

  10. Jensen JD, Jensen LW, Madsen JK (1994) The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. Eur J Clin Pharmacol 46: 333-7. »  CrossRef »  PubMed  »  Google Scholar

  11. Kraegen EW, Chisholm DJ (1985) Pharmacokinetics of insulin. Implications for continuous subcutaneous insulin infusion therapy. Clin Pharmacokinet 10: 303-14. »  CrossRef  »  PubMed  »  Google Scholar

  12. Laursen T, Susgaard S, Jensen FS, Jørgensen JO, Christiansen JS (1994) Absorption kinetics of two highly concentrated preparations of growth hormone : 12 IU/ml compared to 56 IU/ml. Pharmacol Toxicol 74: 54-7. »  CrossRef »  PubMed  »  Google Scholar

  13. Leak LV (1971) Studies on the permeability of lymphatic capillaries. J Cell Biol 50: 300-23. »  CrossRef  »  PubMed  »  Google Scholar

  14. Macdougall IC (2000) Novel erythropoiesis stimulating protein. Seminars in Nephrology 20: 375-81.  »  PubMed  »  Google Scholar

  15. McLennan DN, Porter CJ, Edwards GA, Martin SW, Heatherington AC, et al. (2005) Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep. J Pharmacol Exp Ther 313: 345-51. »  CrossRef  »  PubMed  »  Google Scholar

  16. O’Morchoe CC, O’Morchoe PJ (1987) Differences in lymphatic and blood capillary permeability: ultrastructural-functional correlations. Lymphology 20: 205-9.  »  PubMed  »  Google Scholar

  17. Padhi D, Ni L, Cooke B, Marino R, Jang G (2006) An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 45: 503-10. »  CrossRef  »  PubMed  »  Google Scholar

  18. Russo L, Moore WV (1982) A comparison of subcutaneous and intramuscular administration of human growth hormone in the therapy of growth hormone deficiency. J Clin Endocrinol Metab 55: 1003-6. »  CrossRef  »  PubMed  »  Google Scholar

  19. Schou J (1961) Absorption of drugs from subcutaneous connective tissue. Pharmacol Rev 13: 441-64. »  CrossRef  »  PubMed  »  Google Scholar

  20. Sund RB, Schou J (1964) The determination of absorption rates from rat muscle: An experimental approach to kinetic descriptions. Acta Pharmacol Toxicol 21: 313-25.  »  PubMed  »  Google Scholar

  21. Supersaxo A, Hein WR, Steffen H (1990) Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7: 167-9. »  CrossRef  »  PubMed  »  Google Scholar

  22. Supersaxo A, Hein WR, Steffen H (1991) Mixed micelles as a proliposomal lymphotropic drug carrier. Pharm Res 8: 1286-91. »  CrossRef  »  PubMed  »  Google Scholar

  23. Vahl N, Jensen SB, Rasmussen MH, Susgaard S, Jørgensen JO, et al. (1996) Bioavailability of recombinant Human Growth Hormone in Different concentrations and formulations. Pharmacol Toxicol 79: 144-9.  »  PubMed  »  Google Scholar
 
 
 
This Article
DOWNLOAD
» XML (49 kB)
» PDF (935 kB)
» Citation
   
CONTRIBUTE
» Write a Response
» Read other Responses
» Publishing with OPG
   
SHARE
» E-mail This Article
» Print This Article
» Rights and Permissions
   
Share
EXPLORE
Related Article at
» Pubmed
» DOAJ
» Scholar Google
 
 
 
 
Untitled Document
| More
OMICS Publishing Group: An Open Access Publisher
OMICS Publishing Group is the member of/publishing partner of/source content provider to
All Published content, except where otherwise noted, is licensed under a Creative Commons Attribution License.